Unlocking the Potential of IO102 and IO103: Promising Results from Phase 2 Trial in Combination with Pembrolizumab for Non-Small Cell Lung Cancer and Squamous Cell Carcinoma Treatment

IO Biotech Announces Encouraging Preliminary Data from Phase 2 Trial Overview IO Biotech, a clinical-stage biopharmaceutical company, recently shared promising preliminary data from its Phase 2 basket trial of IO102-IO103 in combination with Merck’s anti-PD-1 therapy KEYTRUDA® at the ESMO Congress in Madrid. This collaboration, known as IOB-022/KN-D38, is a significant step forward in the…

Read More